Sun Pharmaceutical Industries Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹1932.60
Market cap
4,64,171 Cr
Stock P/E
36.8
P/B
5.53
Dividend yield
0.8%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11,941 Cr | 12,192 Cr | 12,381 Cr | 11,983 Cr | 12,653 Cr | 13,291 Cr | 13,675 Cr | 12,959 Cr | 13,851 Cr | 14,478 Cr | 15,521 Cr | 14,612 Cr |
| Operating expenses (approx.) | 8,609 Cr | 9,013 Cr | 8,904 Cr | 8,948 Cr | 9,045 Cr | 9,352 Cr | 9,666 Cr | 9,243 Cr | 9,550 Cr | 9,951 Cr | 10,572 Cr | 10,658 Cr |
| EBITDA | 3,332 Cr | 3,179 Cr | 3,477 Cr | 3,035 Cr | 3,608 Cr | 3,939 Cr | 4,009 Cr | 3,716 Cr | 4,302 Cr | 4,527 Cr | 4,948 Cr | 3,954 Cr |
| OPM % | 27.9% | 26.1% | 28.1% | 25.3% | 28.5% | 29.6% | 29.3% | 28.7% | 31.1% | 31.3% | 31.9% | 27.1% |
| Other income | 204 Cr | 294 Cr | 250 Cr | 606 Cr | 533 Cr | 354 Cr | 466 Cr | 613 Cr | 464 Cr | 470 Cr | 579 Cr | 459 Cr |
| Interest | 81 Cr | 49 Cr | 35 Cr | 74 Cr | 62 Cr | 69 Cr | 52 Cr | 49 Cr | 75 Cr | 100 Cr | 78 Cr | 86 Cr |
| Depreciation | 651 Cr | 633 Cr | 622 Cr | 650 Cr | 655 Cr | 626 Cr | 631 Cr | 664 Cr | 701 Cr | 730 Cr | 732 Cr | 775 Cr |
| Profit before tax | 2,481 Cr | 2,791 Cr | 3,000 Cr | 2,816 Cr | 3,424 Cr | 3,598 Cr | 3,476 Cr | 3,254 Cr | 3,173 Cr | 4,168 Cr | 4,227 Cr | 3,551 Cr |
| Tax % | 18.9% | 14.0% | 14.4% | 5.3% | 16.1% | 15.8% | 16.1% | 33.6% | 27.4% | 24.7% | 19.5% | 23.3% |
| Net profit | 2,006 Cr | 2,385 Cr | 2,561 Cr | 2,659 Cr | 2,861 Cr | 3,037 Cr | 2,913 Cr | 2,154 Cr | 2,293 Cr | 3,125 Cr | 3,381 Cr | 2,710 Cr |
| EPS (₹) | ₹8.40 | ₹9.90 | ₹10.50 | ₹11.10 | ₹11.80 | ₹12.70 | ₹12.10 | ₹9.00 | ₹9.50 | ₹13.00 | ₹14.00 | ₹11.30 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 29,066 Cr | 32,838 Cr | 33,498 Cr | 38,654 Cr | 43,886 Cr | 48,497 Cr | 52,578 Cr | 58,462 Cr | Sign in for TTM |
| Operating expenses (approx.) | 22,758 Cr | 25,848 Cr | 25,007 Cr | 28,257 Cr | 32,239 Cr | 35,474 Cr | 37,307 Cr | 40,731 Cr | Sign in for TTM |
| EBITDA | 6,308 Cr | 6,990 Cr | 8,491 Cr | 10,398 Cr | 11,647 Cr | 13,023 Cr | 15,272 Cr | 17,731 Cr | Sign in for TTM |
| OPM % | 21.7% | 21.3% | 25.3% | 26.9% | 26.5% | 26.9% | 29.0% | 30.3% | Sign in for TTM |
| Other income | 1,025 Cr | 636 Cr | 836 Cr | 922 Cr | 635 Cr | 1,354 Cr | 1,965 Cr | 1,972 Cr | Sign in for TTM |
| Interest | 555 Cr | 303 Cr | 141 Cr | 127 Cr | 172 Cr | 238 Cr | 231 Cr | 339 Cr | Sign in for TTM |
| Depreciation | 1,753 Cr | 2,053 Cr | 2,080 Cr | 2,144 Cr | 2,529 Cr | 2,557 Cr | 2,575 Cr | 2,938 Cr | Sign in for TTM |
| Profit before tax | 3,810 Cr | 5,010 Cr | 2,799 Cr | 4,481 Cr | 9,408 Cr | 11,088 Cr | 13,752 Cr | 15,119 Cr | Sign in for TTM |
| Tax % | 15.8% | 16.4% | 18.4% | 24.0% | 9.0% | 13.0% | 20.2% | 23.5% | Sign in for TTM |
| Net profit | 3,208 Cr | 4,172 Cr | 2,272 Cr | 3,389 Cr | 8,513 Cr | 9,610 Cr | 10,965 Cr | 11,509 Cr | Sign in for TTM |
| EPS (₹) | ₹11.11 | ₹15.69 | ₹12.10 | ₹13.60 | ₹35.30 | ₹39.90 | ₹45.60 | ₹47.80 | Sign in for TTM |
| Dividend payout % | — | — | — | 64.0% | 29.6% | 30.2% | 33.0% | 34.2% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 240 Cr | 240 Cr | 240 Cr | 240 Cr | 240 Cr | 240 Cr | 240 Cr | 240 Cr |
| Reserves | 41,169 Cr | 45,025 Cr | 46,223 Cr | 47,771 Cr | 55,755 Cr | 63,427 Cr | 71,978 Cr | 83,330 Cr |
| Borrowings | — | — | — | — | 6,198 Cr | 2,846 Cr | 1,870 Cr | 4,082 Cr |
| Other liabilities | — | — | — | — | 15,230 Cr | 15,511 Cr | 17,745 Cr | 20,824 Cr |
| Total liabilities | — | — | — | — | 80,744 Cr | 85,463 Cr | 92,101 Cr | 1,08,785 Cr |
| Fixed assets (net) | — | — | — | — | 10,390 Cr | 10,192 Cr | 10,036 Cr | 11,114 Cr |
| CWIP | — | — | — | — | 963 Cr | 1,108 Cr | 1,234 Cr | 1,381 Cr |
| Investments | — | — | — | — | 14,830 Cr | 15,026 Cr | 18,354 Cr | 24,723 Cr |
| Other assets | — | — | — | — | 39,903 Cr | 43,498 Cr | 52,642 Cr | 63,913 Cr |
| Total assets | — | — | — | — | 80,744 Cr | 85,463 Cr | 92,101 Cr | 1,08,785 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 8,985 Cr | 4,959 Cr | 12,135 Cr | 14,072 Cr | 12,419 Cr |
| Cash from investing | — | — | — | -5,725 Cr | -7,944 Cr | -690 Cr | -5,306 Cr | -11,344 Cr |
| Cash from financing | — | — | — | -5,193 Cr | 2,376 Cr | -6,710 Cr | -7,906 Cr | -2,513 Cr |
| Net cash flow | — | — | — | -1,765 Cr | 115 Cr | 4,662 Cr | 983 Cr | -498 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 7,490 Cr | 2,874 Cr | 9,933 Cr | 11,944 Cr | 8,810 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 11.0% | 10.9% | 13.8% | 17.2% | 13.9% | 15.0% | 17.1% | 16.8% |
| ROE % | 6.4% | 8.3% | 6.2% | 6.8% | 14.3% | 14.3% | 15.1% | 13.7% |
| Debtor days | — | — | — | — | 95 | 85 | 90 | 97 |
| Inventory days | — | — | — | — | 492 | 522 | 578 | 566 |
| Days payable | — | — | — | — | 266 | 299 | 349 | 361 |
| Cash conversion cycle | — | — | — | — | 321 | 307 | 319 | 301 |
| Debt / equity | — | — | — | — | 0.11 | 0.04 | 0.03 | 0.05 |
| Current ratio | — | — | — | — | 2.00 | 2.56 | 2.89 | 2.82 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 | -0.49 | -0.55 | -0.32 |
Compare with peers
Loading peers…